Abstract
One decade ago recombinant activated factor VII (rFVIIa) was introduced as a new therapeutic agent for hemophilia patients with inhibitors (Hedner U, 1988). Very soon, its beneficial effect was also proved in many other diseases (Glanzmann’s thrombasthenia, Bernard Soulier thrombopathia, acquired coagulopathy in renal and hepatic failure, congenital deficiency of factor V, VII, XI, acquired hemophilia etc.) (Schulman S, 1998, Martinowitz, 1999). Its clinical use was based on the recognition of the crucial role of FVIIa in hemostasis, initiated both on extrinsic or intrinsic pathway, even in primary hemostasis. The definition of the indications and the optimal therapeutic regimen for rFVIIa is an ongoing process; the establishment of the doses and administration intervals for a minimum hemostatic level is obviously cumbersome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hagen FS, Gray CL, O’Hara P. et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA, 1986, 83: 2413
Hedner U, Bjoern S, Bernvil L et al. Clinical experience with human plasma derived factor VIIa in patients with hemophilia A and high-titer inhibitors. Haemostasis, 1989, 19: 335
Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood, 1989, 73: 359
Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coag and Fibrinol, 1990, 1: 307
Hedner U, Ljunberg J, Lund-Hansen T. Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model. Blood Coag and Fibrinol, 1990, 1: 145
Hedner U, Feldstedt S, Glazer S. Recombinant FVIIa in hemophilia treatment. In: Hemophilia and von Willebrand’s Disease in the 1990s, Lusher JM, Kessler CM, eds, Elsevier Science Publishers B.V., 1991
Schulman S. A therapeutic alternative for haemophiliacs with inhibitors. Acta Paediatr 1992, 81: 926
Ingerslev J, Knudsen L, Sindet-Petersen S. Hemostatic efficacy of recombinant factor VIIa in haemophilia patients with inhibitors. Abstract presented at the XXth International Congress of the World Federation of Haemophilia, Athens, Greece, 1992, 12–17. 10
Kristensen J, Killander A, Hippe E et al. Recombinant factor VIIa (rFVIIa) reduces the bleeding time in patients with thrombocytopenia. Abstract presented at the 35th Annual Meeting of the American Society of Hematology, St. Louis, USA, 1993, 3–7. 12
Rappaport S, Nemerson Y, Kisiel W, Lindhal AK, Morrissey J, Wildgoose P, Lyng Hansen L, Nordfang O, Lund-Hansen T, Lusher JM, Ockelford PA, Ingerslev J, Glazer S, Falch JE A report on the ISTH Satellite Symposium: Recombinant Coagulation Factor VIIa: Mechanism of action and clinical experience, New York, 10.07. 1993, p. 1–15
Glazer S, Hedner U, Falch JE Clinical update of the use of recombinant factor VIIa. Presented at the International Symposium about Inhibitors and Coagulation Factors, Univ. of North Carolina, Chapell Hill, 1993, 3–5. 11.
Ingerslev J. NovoSeven. Clinical Experience and Recommendation, p.1–22, Kontrapunkt A/S, 1995
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Şerban, M., Ţepeneu, P., Petrescu, C., Mihailov, D., Jinca, C., Schramm, W. (2002). Evaluation of Clinical Efficiency of rFVlla in Pediatrics. In: Scharrer, I., Schramm, W. (eds) 31st Hemophilia Symposium Hamburg 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59383-3_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-59383-3_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-42131-3
Online ISBN: 978-3-642-59383-3
eBook Packages: Springer Book Archive